¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"leukocyte common antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • common dorsal mesentery
    ¿ÂµîÂÊâÀÚ°£¸·, ÃѹèÃøÀå°£¸·
  • common duct exploration
    ¿Â¾µ°³°üŽ»ö(¼ú), ÃÑ´ã°üŽ»ö(¼ú)
  • common duct stone
    ¿Â¾µ°³°üµ¹, ÃÑ´ã°ü°á¼®
  • common factor
    °øÅëÀÎÀÚ
  • common hepatic artery
    ¿Â°£µ¿¸Æ, ÃѰ£µ¿¸Æ
  • common hepatic duct
    ¿Â°£°ü, ÃѰ£°ü
  • common iliac artery
    ¿Â¾ûµ¢µ¿¸Æ, ÃÑÀå°ñµ¿¸Æ
  • common iliac lymph node
    ¿Â¾ûµ¢¸²ÇÁÀý, ÃÑÀå°ñ¸²ÇÁÀý
  • common integument
    ¿ÜÇÇ
  • common interosseous artery
    ¿Â»À»çÀ̵¿¸Æ, ÃѰñ°£µ¿¸Æ
  • common nevus
    º¸Åë¸ð¹Ý
  • common opsonin
    Á¤»ó¿É¼Ò´Ñ
  • common palmar digital artery
    ¿Â¹Ù´ÚÂʼհ¡¶ôµ¿¸Æ, ÃÑÀåÃøÁöµ¿¸Æ
  • common palmar digital nerve
    ¿Â¹Ù´ÚÂʼհ¡¶ô½Å°æ, ÃѼöÀåÃøÁö½Å°æ
  • common peroneal nerve
    ¿ÂÁ¾¾Æ¸®½Å°æ, ÃѺñ°ñ½Å°æ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • common hepatic artery
    ¿Â°£µ¿¸Æ
  • common iliac artery
    ¿Â¾ûµ¢µ¿¸Æ
  • common interosseous artery
    ¿Â»À»çÀ̵¿¸Æ
  • common palmar digital artery
    ¿Â¹Ù´ÚÂʼհ¡¶ôµ¿¸Æ
  • common plantar digital artery
    ¿Â¹Ù´ÚÂʹ߰¡¶ôµ¿¸Æ
  • common
    °øµ¿-, º¸Åë-, ¿Â-
  • common cold
    °¨±â
  • common drug
    º¸Åë¾à
  • common epidemic
    °øµ¿°¨¿°¿øÀ¯Çà
  • common factor
    °øÅëÀÎÀÚ
  • common integument
    ¿ÜÇÇ
  • common nevus
    º¸Åë¸ð¹Ý
  • common opsonin
    (¢¡normal opsonin) Á¤»ó¿É¼Ò´Ñ
  • common ratio
    °øºñ
  • common reaction
    Á¤»ó¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • D-related antigen
    D-°ü·ÃÇ׿ø
  • DP antigen
    DPÇ׿ø
  • DQ antigen
    DQÇ׿ø
  • DR antigen
    DRÇ׿ø
  • Diego antigen
    µð¿¡°íÇ׿ø
  • EB nuclear antigen(EBNA0
    EB ¹ÙÀÌ·¯½º ÇÙÇ׿ø
  • EB nuclear antigen (EBNA)
    EB¹ÙÀÌ·¯½º ÇÙÇ׿ø
  • EBV capsid antigen
    EB¹ÙÀÌ·¯½º ĸ½Ãµå Ç׿ø
  • EBV capsid antigen (VCA)
    EB¹ÙÀÌ·¯½º ĸ½ÃµåÇ׿ø
  • EBV membrane antigen
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • EBV membrane antigen (MA)
    EB¹ÙÀÌ·¯½º ¸·Ç׿ø
  • Forssman antigen
    Æ÷½º¸¸Ç׿ø
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gag => group specifiic antigen/core
    ±×·ì<±º>ƯÀ̼º Ç׿ø/ÄÚ¾î
  • Gag antigen in HIV infection
    HIV °¨¿°ÀÇ gag Ç׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • eosinophil leukocyte
    »êÈ£¼º ¹éÇ÷±¸(¡­ÛÜúìϹ).ÀÇÈ£»ê¼º ¹éÇ÷±¸.
  • eosinophil leukocyte
    »êÈ£¼º ¹éÇ÷±¸(?ËÑÌ´Ë´).[ÀÇ]È£»ê¼º ¹éÇ÷±¸.
  • eosinophilic leukocyte
    È£»ê¼º¹éÇ÷±¸
  • globular leukocyte
    ±¸»ó¹éÇ÷±¸(Ë´Ë×ËÑÌ´Ë´).
  • globule leukocyte
    µÕ±Ù°ú¸³¹é¼¼Æ÷
  • granular leukocyte
    °ú¸³¹éÇ÷±¸
  • heterophile leukocyte
    ÀÌ¿°¼º ¹éÇ÷__ì£æøàõÛÜúìϹ).
  • juvenile neutrophilic leukocyte
    ¾î¸°È£Áß¼º¹éÇ÷±¸
  • large mononuclear leukocyte
    ´ë´ÜÇÙ±¸(ÓÞÓ¤ú·Ï¹).
  • large mononuclear leukocyte
    ´ë´ÜÇÙ±¸(ËÀËÀÌ´Ë´).
  • lazy leukocyte syndrome
    Ÿ¸¹éÇ÷±¸ÁõÈıº.
  • leucocyte ; leukocyte
    ¹éÇ÷±¸(ÛÜúìϹ).
  • leukocyte
    ¹éÇ÷±¸
  • leukocyte
    ¹éÇ÷±¸(ÛÜúìϹ).
  • leukocyte
    ¹éÇ÷±¸
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Common iliac vein
    ¿Â¾ûµ¢Á¤¸Æ
    [¿¾ ¿ë¾î] ÃÑÀå°ñµ¿¸Æ
  • Common iliac vein
    ¿Â¾ûµ¢Á¤¸Æ
    [¿¾ ¿ë¾î] ÃÑÀå°ñÁ¤¸Æ
  • Common peroneal nerve
    ¿ÂÁ¾¾Æ¸®½Å°æ
    [¿¾ ¿ë¾î] ÃѺñ°ñ½Å°æ
  • Common pulmonary vein
    ¿ÂÇãÆÄÁ¤¸Æ
    [¿¾ ¿ë¾î] ÃÑÆóÁ¤¸Æ
  • Common peroneal sheath
    Á¾¾Æ¸®±Ù¿ÂÈûÁÙÁý
    [¿¾ ¿ë¾î] ºñ°ñ±ÙÃѰÇÃÊ
  • Common bile duct
    ¿Â¾µ°³°ü
    [¿¾ ¿ë¾î] ÃÑ´ã°ü
  • Sphincter muscle of common bile duct
    ¿Â¾µ°³°üÁ¶ÀÓ±Ù
    [¿¾ ¿ë¾î] ÃÑ´ã°ü°ý¾à±Ù
  • Sphincter of common bile duct
    ¿Â¾µ°³°üÁ¶ÀÓ±Ù
    [¿¾ ¿ë¾î] ÃÑ´ã°ü°ý¾à±Ù
  • Common tendinous ring
    ¿ÂÈûÁÙ°í¸®
    [¿¾ ¿ë¾î] ÃѰǷû
  • COMMON INTEGUMENT
    ¿ÜÇÇ
    [¿¾ ¿ë¾î] ¿ÜÇÇ
  • Common osseous crus
    ¿Â¹Ý°í¸®»À°ü´Ù¸®
    [¿¾ ¿ë¾î] °ñÃѰ¢
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • incomplete antigen
    ºÒ¿ÏÀü Ç׿ø(ÝÕèÇîïù÷ê«)
  • K antigen
    K Ç׿ø
  • LS antigen
    LS Ç׿ø(ù÷ê«)
  • M antigen
    M Ç׿ø(ù÷ê«)
  • MHC antigen
    MHCÇ׿ø(ù÷ê«)
  • NP antigen
    NPÇ׿ø(ù÷ê«)
  • O antigen
    O Ç׿ø(ù÷ê«)
  • P antigen
    P
  • particulate antigen
    ÀÔÀÚ Ç׿ø(Ø£í­ù÷ê«)
  • penton antigen
    ÆæÅæ Ç׿ø(ù÷ê«)
  • protective antigen
    º¸È£ Ç׿ø(ÜÁûÞù÷ê«)
  • R antigen
    R Ç׿ø(ù÷ê«)
  • S antigen
    S Ç׿ø(ù÷ê«)
  • SH-antigen
    SH-Ç׿ø(ù÷ê«)
  • soluble antigen
    °¡¿ëÇ׿ø(ʦéÁù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CALLA Common Acute Lymphocytic(Lymphoblastic) Leukemia Antigen
  = CD10
  = Enk...
cALLA common acute lymphoblastic leukemia antigen
ECA electrical control activity; electrocardioanalyzer; endothelial cytotoxic activity; enterobacterial ...
HLA Human Leukocyte Antigen; ÀιéÇ÷±¸ Ç׿ø
  ? HLA B27 Ag
    (+)·Î ³ª¿À´Â °æ¿ì...
Chi-A chimpanzee leukocyte antigen
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CA Common Antigen
ECA Enterobacterial common antigen
LCA Leucocyte common antigen
CALLA common ALL antigen
ALCAM Activated leukocyte cell adhesion molecule
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • common nasal meatus
    ÃÑ ºñµµ
  • common palmar digital artery
    ¿Â ¹Ù´ÚÂÊ ¼Õ°¡¶ô µ¿¸Æ
  • common pathway
    °øÅë °æ·Î
  • common pharyngeal duct
    ÃÑ ÀεΠ°ü
  • common sense
    °øÅë °¨°¢
    ¸ðµç °¨°ü¿¡ °øÅëµÇ´Â °¨°¢. ÀÏ¹Ý °¨°¢À̶ó°íµµ ÇÑ´Ù. ƯÁ¤ÇÑ °¨°ü¿¡¸¸ ´ëÀÀÇÏ´Â °íÀ¯ÀÇ °¨°¢°ú´Â ±¸º°µÈ´Ù. ¾Æ¸®½ºÅä·¼·¹½ºÀÇ ¡¶Á¤½Å·Ð£ºDe Anima¡·¿¡¼­´Â ¿îµ¿, Á¤Áö, ¼ö, ¸ð¾ç, Å©±âÀÇ Áö°¢À» °øÅë °¨°¢À̶ó Çϰí, ºû±ò¡ª½Ã°¢, ¼Ò¸®¡ªÃ»°¢°ú °°Àº ƯÁ¤ °¨°¢°ú ±¸º°ÇÏ¿´´Ù. T. ¸®µå, A. ÆÛ°Å½¼ µîÀ» Áß½ÉÀ¸·Î ÇÏ´Â ¿µ±¹ÀÇ ¡®»ó½Ä öÇÐ
  • common tendon
    °øÅë ÈûÁÙ, °øÅë °Ç
  • common vehicle spread
    °øÅë ¸Åü¼º ÀüÆÄ
  • accessible antigen
    Á¢±Ù °¡´É Ç׿ø, ±ÙÁ¢ Ç׿ø
  • antigen adjuvant
    Ç׿ø ¾ÆÁê¹ÝÆ®, Ç׿ø º¸°­Á¦
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antigen binding fragment
    Ç׿ø °áÇÕ ºÎÀ§
  • antigen binding site
    Ç׿ø °áÇÕ ºÎÀ§
    ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 3Â÷ ±¸Á¶»ó H ¼â¿Í L ¼âÀÇ °¡º¯¿µ¿ª¿¡¼­ ±¸¼ºµÇ¾î ÀÖ´Â Ç׿ø°ú °áÇÕÇÏ´Â ºÎÀ§.
  • antigen combining site
    Ç׿ø °áÇÕºÎ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
leukocyte adherence assay test A test to detect the ability of leukocytes to adhere to bacteria, performed in vitro using nylon fibres to measure adherence.
(05 Mar 2000)
leukocyte adherence inhibition test Test for cell-mediated antitumour immunity and related serum blocking factors based on the finding that leukocytes from cancer patients, but not from controls, when mixed in vitro with antigenic extracts of tumours of the same histological type, undergo a diminution in their normal adherence to glass surfaces. Sera from tumour-bearing patients block the lai reaction of their own leukocytes or those of other patients with the same type of tumour.
(12 Dec 1998)
leukocyte adhesion deficiency An inherited disorder (autosomal recessive) in which there is a defective CD18 adherence complex that disturbs leukocyte chemotaxis. It is characterised by recurrent bacterial infections and impaired wound healing.
(05 Mar 2000)
leukocyte-adhesion deficiency syndrome <syndrome> Rare, autosomal recessive disorder caused by deficiency of the beta 2 integrin receptors (receptors, leukocyte-adhesion) comprising the CD11/CD18 family of glycoproteins. The syndrome is characterised by abnormal adhesion-dependent functions, especially defective tissue emigration of neutrophils, leading to recurrent infection.
(12 Dec 1998)
leukocyte bactericidal assay test A test of leukocytes to determine their ability to kill a culture of live bacteria.
(05 Mar 2000)
leukocyte count A white blood cell (WBC) count.
(12 Dec 1998)
leukocyte cream <haematology> Thin yellow white layer of leucocytes on top of the mass of red cells when whole blood is centrifuged.
(18 Nov 1997)
leukocyte disorders Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells.
(12 Dec 1998)
leukocyte elastase <enzyme> An enzyme that catalyses the hydrolysis of proteins, including elastin. It cleaves preferentially bonds at the carboxyl side of ala and val, with greater specificity for ala.
Registry number: EC 3.4.21.37
(12 Dec 1998)
leukocyte esterase <enzyme> The presence of leukocyte esterase is indirect evidence for the presence of white blood cells in the urine. The standard urinalysis dip test allows for the quick determination of leukocyte esterase presence via a colour reaction on a urine test strip. A positive test indicates a urinary tract infection.
(27 Sep 1997)
leukocyte inclusions Discrete round or oval body's ranging in diameter from just visible to 2 um, which stain sky blue to gray blue with Romanowsky stains, found in neutrophils of patients with infections, burns, trauma, pregnancy, or cancer.
Synonym: Dohle inclusions, leukocyte inclusions.
(05 Mar 2000)
leukocyte interferon <cytokine> One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells when exposed to live or inactivated virus, double-stranded RNA, or bacterial products.
It is the major interferon produced by virus-induced leukocyte cultures and, in addition to its pronounced antiviral activity, causes activation of NK cells. It is used experimentally in the treatment of hairy-cell leukaemia.
A number of different subtypes exist that are elaborated by leukocytes in response to viral infection or stimulation with double-stranded RNA; IFN-alpha-2A and -2B are protein products made by recombinant DNA techniques and are used as antineoplastic agents.
See: interferon-alpha 2a, interferon-alpha 2b
Synonym: leukocyte interferon.
Pharmacological action: antineoplastic agent, antiviral agent.
(20 Sep 2002)
leukocyte migration-inhibitory factors Protein factor(s) released by sensitised lymphocytes (and possibly other cells) that inhibit the movement of leukocytes, especially polymorphonuclear cells, away from their site of release. Assays for these factors are used as tests for cellular immunity. Two of the common assays are the leukocyte migration capillary tube technique (lmct) and the leukocyte migration agarose technique (lmat).
(12 Dec 1998)
leukocyte transfusion The transfer of leukocytes from a donor to a recipient or reinfusion to the donor.
(12 Dec 1998)
leukocyte tyrosine kinase receptor tyrosine kinase <enzyme> May be receptor for pre-b lymphocyte growth or differentiation factor; aa sequence given in first source
Registry number: EC 2.7.1.-
Synonym: ltk receptor tyrosine kinase, ltk receptor tk, ltk protein, leukocyte tyrosine kinase (ltk)
(26 Jun 1999)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • common lodging (house)
    °£ÀÌ ¼÷¹Ú¼Ò
  • common logarithm
    »ó¿ë ´ë¼ö
  • common market
    °øµ¿½ÃÀå
  • common marketeer
    EEC°¡ÀÔ Âù¼ºÀÚ
  • common measure
    °ø¾à¼ö;=COMMON TIME;º¸Åë·ü µî)
  • common multiple
    °ø¹è¼ö
  • common noun
    º¸Åë ¸í»ç
  • common nuisance
    Ä¡¾È ¹æÇØ
  • common pleas
    ¹Î»ç ¹ý¿ø;¹Î»ç¼Ò¼Û
  • common prayer
    ¼º°øÈ¸ ±âµµ¼­(Àü·Ê¹®)
  • common room
    (Çб³µîÀÇ)±³¿ø ÈÞ°Ô½Ç;(´ëÇÐÀÇ)Ưº° ¿¬±¸¿ø »ç±³½Ç;Çлý À¯°Ô½Ç
  • common school
    °ø¸³ ±¹¹ÎÇб³
  • common seal
    »çÀÎ;(¹ýÀÎÀÇ)°øÀÎ
  • common security
    °øÅëÀÇ ¾ÈÀü º¸Àå
  • common sense
    »ó½Ä;¾ç½Ä(°æÇè¿¡¼­ ¾òÀº »ç¸® ºÐº°);ÀϹÝÀÎ °øÅëÀÇ ´À³¦(°¨°¢)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á